Call for Abstracts
Updated Friday, November 10 (Fri), 2023
The submission for the final, updated late-breaking data for Late-breaking Abstract is now open.
E-mail notification has been sent to those who have already made a provisional registration. Please check your e-mail and submit your abstract by the deadline.
Deadline for submitting the final, updated late-breaking data: Thursday, December 15 (Fri), 2023, noon (JST)
Late-breaking Abstracts submission has been closed.
If you have difficulty in submitting your abstract by the above deadline, please contact the abstract submission section of Congress Secretariat （jsmo2024-abs@congre.co.jp）
If you are Japanese, please declare your COI and submit your abstract to the Japanese website.
- Abstract Submission Period
- Call for Abstracts
- JSMO 2024’s virtual session website
- Abstract Young Investigator Award
- Late-breaking Abstracts
- Presidential Session
- Highlight of the Day
- Travel Award
- Publication in "Annals of Oncology"
- Disclosure of Conflict of Interest at 2024 the Japanese Society of Medical Oncology Annual Meeting
- Ethical Principles for Declaring Ethical Matters of your Abstract
- Abstract Submission
- Confirmation / Modification / Deletion of Submitted Abstract & Additional Submission
- Acceptance/Rejection Notification
Abstract Submission Period
Noon, Thursday, June 15, 2023 – Noon, Friday, September 15, 2023 (JST) →Noon, Friday, September 29, 2023 (JST)
Extended until Fri, Sep 29. We look forward to your submissions!
Abstract Submission has been closed. Thank you for your submission!
Call for Abstracts
General Abstract (Oral / Poster Presentation)
JSMO2024 accepts abstracts for General Abstract.
The Oral and Poster presentations will be given and held on-site.
Please select the abstract category from the list below. (The 1st & 2nd choices are required.)
↓ Swipe sideways to see.
| Category | Sub-Category | Presentation Style |
|---|---|---|
| 01．Gastrointestinal Cancer | 01-01. Esophageal Cancer | Oral / Poster |
| 01-02. Gastric Cancer | ||
| 01-03. Small Bowel Cancer | ||
| 01-04. Colorectal Cancer | ||
| 01-05. Other (Appendix Cancer, Anal Cancer, etc.) | ||
| 02．Hepatobiliary/ Pancreatic Cancer | 02-01. Liver Cancer | Oral / Poster |
| 02-02. Gallbladder and Biliary Tract Cancer | ||
| 02-03. Pancreatic Cancer | ||
| 03．Lung Cancer/ Thoracic Cancer | 03-01. Early Stage Non-Small Cell Lung Cancer/Perioperative Treatment | Oral / Poster |
| 03-02. Locally Advanced Non-Small Cell Lung Cancer | ||
| 03-03. Metastatic Non-Small Cell Lung Cancer/Chemotherapy | ||
| 03-04. Metastatic Non-Small Cell Lung Cancer/Tyrosine Kinase Inhibitor | ||
| 03-05. Metastatic Non-Small Cell Lung Cancer/Immunotherapy | ||
| 03-06. Small Cell Lung Cancer | ||
| 03-07. Other (Mesothelioma, Thymic Malignancies, etc.) | ||
| 04．Hematologic Malignancies | 04-01. Lymphoma | Oral / Poster |
| 04-02. Leukemia | ||
| 04-03. Other (Myeloma etc.) | ||
| 05．Breast Cancer | 05-01. Early Breast Cancer/Perioperative Therapy | Oral / Poster |
| 05-02. Metastatic Breast Cancer | ||
| 06．Gynecologic Cancer | 06-01. Gynecologic Cancer | Oral / Poster |
| 07．Genitourinary Cancer | 07-01. Genitourinary Cancer | Oral / Poster |
| 08．Head and Neck Cancer | 08-01. Head and Neck Cancer | Oral / Poster |
| 09．Rare Cancer/ Cancer of Unknown Primary | 09-01. Pediatric Oncology | Oral / Poster |
| 09-02. Central Nervous System Tumors | ||
| 09-03. Endocrine Cancer, Thyroid Cancer, Neuroendocrine Tumor | ||
| 09-04. Skin Cancer | ||
| 09-05. Sarcoma | ||
| 09-06. Germ Cell Tumor | ||
| 09-07. Cancer of Unknown Primary | ||
| 09-08. Other | ||
| 10．Translational Research/ Clinical Pharmacology | 10-01. Basic Research | Oral / Poster |
| 10-02. Clinical Pharmacology | ||
| 10-03. Innovative Drug Research & Development | ||
| 10-04. Molecular Diagnostics/Genomic Medicine | ||
| 10-05. Translational Research | ||
| 10-06. Companion Diagnostics | ||
| 10-07. Developmental Therapeutics | ||
| 10-08. Other | ||
| 11．Palliative Care/Symptom Management | 11-01. Palliative Medicine | Oral / Poster |
| 11-02. Symptom Management | ||
| 11-03. Oral Care for Cancer Patients | ||
| 11-04. Psycho-Oncology | ||
| 11-05. Other | ||
| 12．Cross-sectional Program | 12-01. Radiation Oncology | Oral / Poster |
| 12-02. Diagnostic Imaging | ||
| 12-03. Familial and Hereditary Cancer | ||
| 12-04. Epidemiology | ||
| 12-05. Cancer Prevention | ||
| 12-06. Immunobiology and Immunotherapy | ||
| 12-07. Drug Therapy | ||
| 12-08. Other | ||
| 13．Multidisciplinary Team Program | 13-01. Interdisciplinary Approach to Cancer Care | Oral / Poster |
| 13-02. Rehabilitation | ||
| 13-03. Outpatient Chemotherapy | ||
| 13-04. Professional Oncology Education | ||
| 13-05. Oncology Nursing | ||
| 13-06. Other | ||
| 14．Clinical Trial Facilitation Program | 14-01. Biostatistics | Oral / Poster |
| 14-02. Clinical Trial Support | ||
| 14-03. Trials in Progress (a) | ||
| 14-04. Research Ethics | ||
| 14-05. Health Policy/Regulatory Affairs/Reimbursement | ||
| 14-06. Health Technology Assessment/Health Economics | ||
| 14-07. Other | ||
| 15．Patient Advocacy/Survivorship | 15-01. Patient Advocacy | Oral / Poster |
| 15-02. Survivorship | ||
| 15-03. Geriatric Oncology | ||
| 15-04. Community Cancer Care | ||
| 15-05. Adolescents and Young Adults with Cancer | ||
| 15-06. Other | ||
| 16 Medical Case Report | 16-01. Rare Cancer | Poster |
| 16-02. Lung | ||
| 16-03. Gastrointestinal Tract | ||
| 16-04. Hematologic Malignancies | ||
| 16-05. Breast | ||
| 16-06. Solid Cancers | ||
| 17 Artificial Intelligence (AI) | 17-01. Artificial Intelligence (AI) | Oral / Poster |
| 18．Miscellaneous | 18-01．Miscellaneous | Oral / Poster |
- (a)Abstracts submitted under the “Trials in Progress” category (14-03) will be posted on the program application and handed out to the participants at the venue on the day of the session.
Abstract Young Investigator Award
- Age limitation: The first author must be under the age 40 (as of February 24, 2024)
- Once you are nominated as a candidate, you will be requested to submit an electronic data (Powerpoint presentation slides) for review in December 2023.
- Details will be notified to nominees.
If you would like to be reviewed as a candidate, please check the box to be reviewed as the candidate for the Abstract Young Investigator Award.
Late-breaking Abstracts
JSMO2024 would like to deepen discussions based on the latest research results. We accept such abstracts as "Late-breaking abstracts".
If you are applying for Late-breaking abstracts, please select "Yes" for the question, "Are you applying for late-breaking abstracts?" and submit an outline and predicted results of your research as interim registration in the abstract text box.
The submission for the final, updated late-breaking data is planned to open in early December, and run till late December 2023.
The accepted results are not influenced even if the actual research results were different from your prediction.
Presidential Session
JSMO2024 will select abstracts to be presented in "Presidential Sessions" from the submitted abstracts this year instead of usual Plenary Session. The selection flow is as follows.
Step 1:
The program committee members recommend the following number of abstracts from each category.
38 abstracts in total: 6 abstracts from each Gastrointestinal Cancer and Lung Cancer /Thoracic Cancer, and each 2 abstracts from other category.
Step 2:
Congress president selects 12 abstracts out of 38 abstracts, and the final selection will be made at the program committee.
Highlight of the Day
Of all the presentations on each day, those with the greatest impact will be selected for review the day after the presentation.
Travel Award
Abstracts submitted by young researchers from outside Japan will be reviewed by the JSMO2024 committee members. Those selected presenters will be awarded partial travel grant for their outstanding works. Abstracts authors are encouraged to apply for Travel Award as outlined below:
Award Details
- JPY 50,000–100,000 of travel support to investigators from Asia (depending on the quality of abstract).
- JPY 150,000 of travel support to investigators from others.
- Congress registration to JSMO2024 is waived
- Hotel accommodation while you stay in Japan (Single room for up to four nights).
Note: To qualify for the travel award, you must be free of any commercial grants or support.
Application Acceptance Period
Noon, Thursday, June 15, 2023 – Noon, Friday, September 15, 2023 (JST)
(same as the application period for JSMO2024 abstracts)
Eligible Applicants
- Applicants must be young overseas doctors / researchers, who live outside of Japan, age 45 years old or younger, as of February 24, 2024 (the last day of JSMO2024).
- Applicants receiving commercial grant support or financial assistance are ineligible
How to Apply
Please apply by submitting your abstract from the Submission Page (click the "Submit" button).
Award Notification
Recipients will be notified by e-mail in the middle December 2023.
Publication in "Annals of Oncology"
Abstracts (oral / poster) submitted in English for JSMO2024 will be published in ESMO/JSMO Scientific Journal, supplement to "Annals of Oncology" (Elsevier).
If you wish to have your abstract published in "Annals of Oncology," please select "Yes".
However, in case that there is any possibility of duplicate publication or encore publication, please refrain from selecting "Yes".
- Terms to be published in Journal "Annals of Oncology" as to poster presentation:
Oral presentations are free of charge but poster presentations are required 5,000JPY of the posting fee of "Annals of Oncology" in addition to the Congress registration fee.
You can cancel publication of the journal after the acceptance notice.
We will contact you to confirm your final intention when the presentation style is decided.
Disclosure of Conflict of Interest at 2024 the Japanese Society of Medical Oncology Annual Meeting
The presenter (the first author) and the principal investigator must disclose the name of any company or for-profit organization related to medicine they have a relationship with, defined as follows: in the following items (3) to (9), (11), (12), exceeding separately stipulated criteria, and (1), (2), (10), (13) if met. The subject period is from January 1, 2020 - December 31, 2022.
To view the PDF files, you may need, "Adobe Reader" (Download Adobe Reader）
COI Policy (in revision)
Detailed Enforcement Regulations of COI (in revision)
For oral presentation, please use the slide below as a template to disclose conflict of interest.
For poster presentation, please prepare and print out the slide, and put it at lower right of the poster panel.
↓ Swipe sideways to see.
| 1 | If your study for this presentation is supported by research funds |
|---|---|
| 2 | If you are or have been an employee of a company and / or a profit-making organization related to medicine |
| 3 | If you have earned > ¥1,000,000 / year as an officer or advisor of a company and/or a profit-making organization related to medicine |
| 4 | If you hold > 5% of the stock of a company and/or a profit-making organization related to medicine, or receive dividends >¥1,000,000/year |
| 5 | If you have earned > ¥1,000,000/year as a patent fee from a company and / or a profit-making organization related to medicine |
| 6 | If you have earned > ¥500,000/year as a lecture fee from a company and / or a profit-making organization related to medicine |
| 7 | If you have earned > ¥500,000/year as a manuscript fee from a company and / or a profit-making organization related to medicine |
| 8 | If you have received > ¥1,000,000/year as research expenses from a company and / or a profit-making organization related to medicine |
| 9 | If you have received > ¥1,000,000/year as a certain contribution from a company and / or a profit-making organization related to medicine |
| 10 | If you are or have been involved in a certain endowed chair funded by a company and / or a profit-making organization related to medicine |
| 11 | If you have earned > ¥1,000,000/year as a fee for expert comment, judgment or testimony in legal proceedings, or others froma company and / or a profit-making organization related to medicine |
| 12 | If you have received remuneration (travel, gifts, or other in-kind payments not directly related to research) equivalent to >¥50,000/year from a company and / or a profit-making organization related to medicine |
| 13 | If you are a representative of an organization for clinical study which receives research expenses (donation, contract, others)from a company and/or a profit-making organization related to medicine |
Inquiries regarding COI disclosure
- The Secretariat of the Japanese Society of Medical Oncology
- E-mail: support@jsmo.or.jp
Ethical Principles for Declaring Ethical Matters of your Abstract
In order to review whether your abstract is conformed to the standard of applicable research ethics such as "GCP", "GPSP", "Ethical guidelines on medical research on humans", "Ethical guidelines on research on human genome and gene analysis", etc., JSMO asks you to declare the following items:
The content of your declaration will not affect the acceptance or rejection of your abstract. Please submit to the following:
- Does your study include medical research on human subjects, human material or human data? *Required
- Does your study comply with the Declaration of Helsinki?
- Was your study approved by an institutional review board before starting the research?
Abstract Submission
Important note to those whose study includes Japanese participants.
Previously, you had been directed to the Japanese website, however, the guideline has changed.
From now on, please access the English website for all submissions.
Guideline
We accept abstracts submitted online only through the submission system.
You may enter the submission page from "Abstract Submission" button at the bottom of this page.
- Author information and abstracts must be submitted in English.
- Abstract title must be up to 120 single-byte characters.(including spaces)
- Abstract text must be up to 2,000 single-byte characters.(including spaces)
- The maximum of 20 authors (first author & co-authors) can be registered.
- The maximum of 20 affiliations (including the affiliation of the first author) can be registered.
- Please structure your abstract as follows:
- Background:
- Methods:
- Results:
- Conclusion:
- Any chart or diagram cannot be included.
- In the registration page, you will be asked to enter the information such as "application for Young Investigator Award",
"application for Travel Award", "about in Encore Abstract", "about Presented Abstract",
"application for Late-breaking abstracts", "publication in Annals of Oncology" as well as COI information.
- It is recommended that you prepare your abstract text by Word/ text file in advance, and then copy it on the registration page.
- After completing the abstract submission, the abstract registration ID number and your password will be sent to the first author’s email address. The ID number and password will be required to confirm/modify/delete/add abstracts. Please be sure to enter the correct e-mail address. Please be sure to keep the ID number and password by yourself. The congress secretariat will NOT keep track of your information.
Confirmation / Modification / Deletion of Submitted Abstract & Additional Submission
You can access to confirm/modify/delete/add abstracts during the abstract submission period.
The ID number and password will be required to enter the page (confirm/modify/delete/add abstracts).
Acceptance/Rejection Notification
All submitted abstracts will be reviewed by the Peer Review Committee and decided comprehensively based on the study contents,ethical aspects, and etc. You may choose the presentation style (oral or poster) when you submit an abstract. However, pleaseunderstand that the congress president will make a final decision on the presentation style, presentation session, as well asacceptance/rejection.
Notification of acceptance/rejection will be sent to the first author by email in the early of December, 2023.
Abstract Submission
Confirmation / Modification / Deletion of submitted abstract & Additional submission Page
Inquiries for Abstract Submission
- Congress Secretariat
- c/o Congrès Inc.
- Onward Park Bldg., 3-10-5 Nihonbashi, Chuo-ku Tokyo 103-8276, JAPAN
- E-mail：jsmo2024-abs@congre.co.jp